All topics
Life Sciences · Updated yesterday
Biotechnology
Programmable biology and CRISPR therapeutics reach the clinic.
Consensus
63
0–100 index
Momentum
+47
+47%
90-day
Sources
59
Cross-category
Publications
224
Indexed
Executive Summary · AI Synthesis
Across 59 monitored sources, the dominant narrative on Biotechnology is one of accelerating adoption coupled with structural bottlenecks. Tier-1 consultancies converge on the value thesis; scientific and international bodies remain more measured on societal impact and timelines.
Key Insights
Insight
In-vivo CRISPR
First approvals expand rapidly.
Consensus Matrix
Alignment of leading sources on Biotechnology.
MK
McKinsey & Company
++BCG
BCG
++DL
Deloitte Insights
+AC
Accenture Research
++GT
Gartner
+N
Nature
●MIT
MIT Technology Review
+OE
OECD
●Diverging Opinions
Where sources disagree.
McKinseyvsNature
Near-term productivity impact
Bullish vs NeutralGartnervsOECD
Labour displacement pace
Fast vs GradualBCGvsMIT
Agentic AI enterprise readiness
High vs SelectiveTimeline
Publications and consensus over time.
2019
2020
2021
2022
2023
2024
2025
2026
Related Topics
Source Explorer
- No reports indexed yet for this topic.